SEC Form 4 · accession 0001209191-17-002649
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth E Reed
Officer — SVP, GC & Corporate Secretary
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 4, 2017 | A | 10,000 | $0.00 | A | 10,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (Right to Buy)F1 | $19.08 | Jan 4, 2017 | A | 50,000 | A | — | Jan 3, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1One fourth of the shares subject to the stock option shall vest and become exercisable on the first anniversary of the date of grant, and the remaining shares shall vest and become exercisable in twelve equal quarterly installments thereafter.